161 related articles for article (PubMed ID: 24801755)
1. Anti-galectin-3 therapy: a new chance for multiple myeloma and ovarian cancer?
Mirandola L; Nguyen DD; Rahman RL; Grizzi F; Yuefei Y; Figueroa JA; Jenkins MR; Cobos E; Chiriva-Internati M
Int Rev Immunol; 2014 Oct; 33(5):417-27. PubMed ID: 24801755
[TBL] [Abstract][Full Text] [Related]
2. Galectin-3 inhibition suppresses drug resistance, motility, invasion and angiogenic potential in ovarian cancer.
Mirandola L; Yu Y; Cannon MJ; Jenkins MR; Rahman RL; Nguyen DD; Grizzi F; Cobos E; Figueroa JA; Chiriva-Internati M
Gynecol Oncol; 2014 Dec; 135(3):573-9. PubMed ID: 25284038
[TBL] [Abstract][Full Text] [Related]
3. Role of Galectins in Multiple Myeloma.
Storti P; Marchica V; Giuliani N
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29258207
[TBL] [Abstract][Full Text] [Related]
4. Varied expression and localization of multiple galectins in different cancer cell lines.
Satelli A; Rao PS; Gupta PK; Lockman PR; Srivenugopal KS; Rao US
Oncol Rep; 2008 Mar; 19(3):587-94. PubMed ID: 18288388
[TBL] [Abstract][Full Text] [Related]
5. [Tandem transplantation with peripheral autologous hematopoietic blood stem cells in treatment of oncologic and hematologic malignancies. Initial results of the Donauspital, Vienna].
Ruckser R; Kier P; Sebesta C; Kittl E; Kurz M; Selleny S; Höniger S; Scherz M; Habertheuer KH; Zelenka P
Wien Med Wochenschr; 1995; 145(2-3):41-4, 46-7. PubMed ID: 7762251
[TBL] [Abstract][Full Text] [Related]
6. Galectins in hematological malignancies.
Giordano M; Croci DO; Rabinovich GA
Curr Opin Hematol; 2013 Jul; 20(4):327-35. PubMed ID: 23695449
[TBL] [Abstract][Full Text] [Related]
7. Advances in immunotherapy of multiple myeloma: from the discovery of tumor-associated antigens to clinical trials.
Chiriva-Internati M; Cobos E; Kast WM
Int Rev Immunol; 2007; 26(3-4):197-222. PubMed ID: 17558744
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in multiple myeloma: current strategies and future prospects.
Yi Q
Expert Rev Vaccines; 2003 Jun; 2(3):391-8. PubMed ID: 12903804
[TBL] [Abstract][Full Text] [Related]
9. Ovarian cancer biology and immunotherapy.
Latha TS; Panati K; Gowd DS; Reddy MC; Lomada D
Int Rev Immunol; 2014 Oct; 33(5):428-40. PubMed ID: 24911597
[TBL] [Abstract][Full Text] [Related]
10. Human galectins induce conversion of dermal fibroblasts into myofibroblasts and production of extracellular matrix: potential application in tissue engineering and wound repair.
Dvořánková B; Szabo P; Lacina L; Gal P; Uhrova J; Zima T; Kaltner H; André S; Gabius HJ; Sykova E; Smetana K
Cells Tissues Organs; 2011; 194(6):469-80. PubMed ID: 21494018
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for ovarian cancer: recent advances and perspectives.
Zsiros E; Tanyi J; Balint K; Kandalaft LE
Curr Opin Oncol; 2014 Sep; 26(5):492-500. PubMed ID: 25036883
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma.
van de Donk NW; Kamps S; Mutis T; Lokhorst HM
Leukemia; 2012 Feb; 26(2):199-213. PubMed ID: 21852787
[TBL] [Abstract][Full Text] [Related]
13. Galectin-9 exhibits anti-myeloma activity through JNK and p38 MAP kinase pathways.
Kobayashi T; Kuroda J; Ashihara E; Oomizu S; Terui Y; Taniyama A; Adachi S; Takagi T; Yamamoto M; Sasaki N; Horiike S; Hatake K; Yamauchi A; Hirashima M; Taniwaki M
Leukemia; 2010 Apr; 24(4):843-50. PubMed ID: 20200560
[TBL] [Abstract][Full Text] [Related]
14. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
Lauta VM
Cancer; 2003 May; 97(10):2440-52. PubMed ID: 12733143
[TBL] [Abstract][Full Text] [Related]
15. Galectin-3--a jack-of-all-trades in cancer.
Newlaczyl AU; Yu LG
Cancer Lett; 2011 Dec; 313(2):123-8. PubMed ID: 21974805
[TBL] [Abstract][Full Text] [Related]
16. Prospects and challenges for immunotherapy of ovarian cancer--what can we learn from the tumor microenvironment?
Chiriva-Internati M; Cobos E; Cannon MJ
Int Rev Immunol; 2011; 30(2-3):67-70. PubMed ID: 21557634
[TBL] [Abstract][Full Text] [Related]
17. Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.
Chen YX; Wang Y; Fu CC; Diao F; Song LN; Li ZB; Yang R; Lu J
Endocr Relat Cancer; 2010 Mar; 17(1):39-50. PubMed ID: 19776289
[TBL] [Abstract][Full Text] [Related]
18. Peptides specific to the galectin-3 carbohydrate recognition domain inhibit metastasis-associated cancer cell adhesion.
Zou J; Glinsky VV; Landon LA; Matthews L; Deutscher SL
Carcinogenesis; 2005 Feb; 26(2):309-18. PubMed ID: 15528216
[TBL] [Abstract][Full Text] [Related]
19. Humoral immunotherapy of multiple myeloma: perspectives and perplexities.
Di Bernardo A; Macor P; Guarnotta C; Franco G; Florena AM; Tedesco F; Tripodo C
Expert Opin Biol Ther; 2010 Jun; 10(6):863-73. PubMed ID: 20367529
[TBL] [Abstract][Full Text] [Related]
20. Current management and emerging treatment strategies for multiple myeloma.
Lei M; Kim EB; Branagan A; Lou U; Zemel M; Raje N
Rinsho Ketsueki; 2019; 60(9):1243-1256. PubMed ID: 31597850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
